Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Dec 20, 2006

QLT Earmarks $1.45M for AMD Research at Wilmer Eye Institute

  • QLT will research and develop potential treatments for dry age-related macular degeneration (AMD), under a two-year research collaboration and option agreement with the Wilmer Eye Institute at Johns Hopkins University.

    The agreement provides QLT with the first option to negotiate an exclusive license to patented products resulting from the research that could ultimately prevent the production and accumulation of toxic lipids in the eye that are believed to be key early events in dry AMD.

    Under the terms of the agreement, Johns Hopkins University will receive $1.45 million in research funding over two years. If QLT exercises its license option, it will pay Johns Hopkins certain financial milestones and royalties.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »